Patents Assigned to Inserm
  • Inhibitors of cyclophilins and uses thereof
    Patent number: 8802666
    Abstract: The present invention relates to a compound of formula (I): wherein: n is 0, 1 or 2; A is in particular CH or N; X is in particular CO, SO2, CS, and R1 is in particular H, R2 is a group of formula NR3R4 or OR5, R3 and R4 being in particular H, and R5 an alkyl group, R6 is in particular H or an alkyl group, and R7 is in particular an aryl group, for its use in the prevention and/or the treatment of viral pathologies or infections.
    Type: Grant
    Filed: December 21, 2010
    Date of Patent: August 12, 2014
    Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Jean-Francois Guichou, Lionel Colliandre, Hakim Ahmed-Belkacem, Jean-Michel Pawlotsky
  • Method for the hypothermic perfusion of a cardiac organ, and device for the implementation thereof
    Patent number: 8802425
    Abstract: A device for hypothermic perfusion of a cardiac organ comprising a first sealed tank able to contain a physiological liquid, a second sealed tank communicating, in a sealed manner, with an internal volume of the first tank via a nozzle, a device for refrigerating the first tank and keeping the first tank at a substantially constant temperature and a device for intermittently pressurizing the internal volume of the first tank. The first tank communicates with the pressurizing device by way of a conduit connecting an interior of the first tank to the pressurizing device to permit pressurization of the internal volume of the first tank, and of the physiological liquid inside the first tank, in order to perform perfusion of the organ. The second tank comprises a safety element formed by an overflow outlet duct which communicates with the first tank and includes a non-return valve.
    Type: Grant
    Filed: December 8, 2010
    Date of Patent: August 12, 2014
    Assignees: Universite Claude Bernard Lyon I, INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventor: René Ferrera
  • METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CARDIOMYOPATHY DUE TO FRIEDREICH ATAXIA
    Publication number: 20140221462
    Abstract: A method for preventing or treating cardiomyopathy due to energy failure in a subject in need thereof is provided. The method comprises administering to the subject a therapeutically effective amount of a vector which comprises a nucleic acid sequence encoding a gene that can reverse energy failure. An exemplary cardiomyopathy is that which is associated with Friedreich ataxia and an exemplary nucleic acid sequence comprises a nucleic acid that encodes frataxin (FXN).
    Type: Application
    Filed: February 1, 2013
    Publication date: August 7, 2014
    Applicants: Institut National de la Sante et de la Recherche Medicale (INSERM), Cornell Center for Technology, Enterprise & Commercialization, Universite de Strasbourg, CNRS (Centre National de la Recherche Scientifique)
    Inventors: Helene Monique Puccio, Patrick Aubourg, Ronald G. Crystal
  • Methods for Determining the Oncogenic Condition of Cell, Uses Thereof, and Methods for Treating Cancer
    Publication number: 20140221353
    Abstract: The invention relates to methods for detecting the oncogenic condition of cells, including step where the amount of the OCDO compound in said cells is measured, and to the uses thereof. The invention further relates to OCDO inhibitors for use in methods for treating cancer.
    Type: Application
    Filed: December 5, 2013
    Publication date: August 7, 2014
    Applicants: Affichem, INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Philippe De Medina, Michael Paillasse, Marc Poirot, Sandrine Silvente-Poirot
  • POLYMER PARTICLES OR NANO-VECTORS AND USE THEREOF AS A DRUG AND/OR DIAGNOSTIC AGENT
    Publication number: 20140219925
    Abstract: Novel polymer nanovectors or particles and use thereof as medication and/or diagnostic agents.
    Type: Application
    Filed: June 28, 2012
    Publication date: August 7, 2014
    Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Philippe Bertrand, Regis Delatouche, Valerie Heroguez, Floraine Collette, Marc Gregoire, Christophe Blanquart, Fabien Gueugnon
  • NOVEL MUTATED TISSUE PLASMINOGEN ACTIVATORS AND USES THEREOF
    Publication number: 20140212406
    Abstract: The present invention relates to mutated tissue plasminogen activators, and their use for treating thrombotic diseases.
    Type: Application
    Filed: September 7, 2012
    Publication date: July 31, 2014
    Applicant: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Denis Viven, Jerome Parcq
  • Multimodular assembly useful for intracellular delivery
    Patent number: 8790664
    Abstract: A stabilized multimodular assembly for intracellular delivery comprising a complex of at least one cationic transfection agent and of at least one negatively charged macromolecule, wherein the complex has a theoretical charge ratio ranging from about 0 to about 4, and an efficient amount of at least one amphiphilic block co-polymer acting as a steric colloidal stabilizer with respect to the complex, the block co-polymer having hydrophilic and hydrophobic blocks wherein at least one hydrophilic block is conjugated with at least one targeting ligand.
    Type: Grant
    Filed: September 2, 2009
    Date of Patent: July 29, 2014
    Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Bruno Pitard, Charles Tellier, Corinne Miral, Emilie Letrou-Bonneval
  • Promyelocytic Leukemia Protein as a Redox Sensor
    Publication number: 20140205568
    Abstract: The present invention relates to a method for determining the redox status of a cell or tissue comprising a step consisting of determining the level of PML nuclear bodies in said cell or tissue.
    Type: Application
    Filed: March 7, 2014
    Publication date: July 24, 2014
    Applicant: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Hugues De The, Valerie Lallemand-Breitenbach
  • Methods and Pharmaceutical Compositions for the Treatment of Respiratory Tract Infections
    Publication number: 20140206601
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of respiratory tract infections. More particularly, the present invention relates to a TLR5 agonist for use in a method for treating a respiratory tract infection.
    Type: Application
    Filed: February 20, 2014
    Publication date: July 24, 2014
    Applicants: Institut Pasteur de Lille, Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Jean-Claude Sirard, Jose A. Chabalgoity
  • Use of FSH receptor ligands for diagnosis and therapy of cancer
    Patent number: 8784776
    Abstract: The present invention relates to diagnostic imaging and in particular to the diagnostic imaging and therapy of cancer by means of compositions which specifically target the FSH Receptor expressed by tumor endothelial cells and circulating blood cells.
    Type: Grant
    Filed: February 18, 2009
    Date of Patent: July 22, 2014
    Assignees: Inserm (Institut National de la Sante et de la Recherche Medicale), Mount Sinai School of Medicine
    Inventors: Nicolae Ghinea, Aurelian Radu
  • Monovalent ligands of the human CD28 receptor
    Patent number: 8785138
    Abstract: The invention relates to monovalent ligands of the human CD28 receptor, which can selectively block the interaction between CD28 and B7 without activating the CD28 receptor. Said ligands can be used in particular in the production of immunosuppressant drugs, selectively blocking T lymphocyte activation phenomena involving the CD28 receptor.
    Type: Grant
    Filed: October 8, 2010
    Date of Patent: July 22, 2014
    Assignees: Effimune, Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Bernard Vanhove, Caroline Mary
  • Anti-CD28 humanized antibodies
    Patent number: 8785604
    Abstract: The invention relates to humanized antibodies directed against the human lymphocyte receptor CD28. When used in a monovalent form these antibodies are antagonists, i.e. capable of blocking of the CD28/B7 interaction, without activating CD28. These antibodies can be used in particular as therapeutic agents for blocking T cell activation through the CD28 receptor.
    Type: Grant
    Filed: February 16, 2011
    Date of Patent: July 22, 2014
    Assignees: Effimune, Insitut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Caroline Mary, Nicolas Poirier, Bernard Vanhove
  • Methods, pharmaceutical compositions and kits for use in the treatment of adult T-cell leukemia/lymphoma
    Patent number: 8784797
    Abstract: The present invention relates to methods, pharmaceutical compositions and kits for use in the treatment of Adult T-cell leukemia/lymphoma. More particularly, the present invention relates to a combination of an interferon, an arsenic compound and a reverse transcriptase inhibitor for the treatment of Adult T-cell leukemia/lymphoma.
    Type: Grant
    Filed: December 15, 2009
    Date of Patent: July 22, 2014
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), American University of Brirut
    Inventors: Hugues De The, Ali Bazarbachi, Olivier Hermine
  • Inhibitors of Cathepsin S for Prevention or Treatment of Obesity-Associated Disorders
    Publication number: 20140199326
    Abstract: The present invention relates to methods (and pharmaceutical compositions) for treating and/or preventing for obesity associated disorders, particularly related to a deregulation of glucose homeostasis, by administrating Cathepsin S inhibitors. The invention also relates to methods for diagnosing insulin resistance and glucose tolerance by measuring Cathepsin S levels in a biological sample obtained from a subject.
    Type: Application
    Filed: February 12, 2014
    Publication date: July 17, 2014
    Applicant: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Karine Clement, Michele Guerre Millo, Nadia Naour
  • Antagonists of CB1 Receptor
    Publication number: 20140200200
    Abstract: The invention relates to an antagonist of CB1 receptor for use in the treatment of a pathologic condition or disorder selected from the group consisting of bladder and gastrointestinal disorders; inflammatory diseases; cardiovascular diseases; nephropathies; glaucoma; spasticity; cancer; osteoporosis; metabolic disorders; obesity; addiction, dependence, abuse and relapse related disorders; psychiatric and neurological disorders; neurodegenerative disorders; autoimmune hepatitis and encephalitis; pain; reproductive disorders and skin inflammatory and fibrotic diseases.
    Type: Application
    Filed: May 18, 2012
    Publication date: July 17, 2014
    Applicants: UNIVERSITE DE BORDEAUX I, INSERM (Institut National de la Sante et de la Recherche Medicale), UNIV DE BORDEAUX II VICTOR SEGALEN
    Inventors: Pier Vincenzo Piazza, Monique Vallee, Giovanni Marsicano, Francois-Xavier Felpin, Luigi Bellocchio, Daniela Cota, Jean-Michel Revest, Sergio Vitiello, Umberto Spampinato, Rafael Maldonado
  • Combination of a Statin and a Taxane for the Treatment of Gastric Cancer
    Publication number: 20140200269
    Abstract: The present invention relates to a combination of (i) a statin, and (ii) a taxane, for simultaneous or sequential use in the treatment of a patient suffering from solid tumor, e.g. a gastric cancer. The present invention also provides a statin, for use in a method for enhancing sensitivity of a patient suffering from a solid tumor to a taxane.
    Type: Application
    Filed: May 10, 2012
    Publication date: July 17, 2014
    Applicants: INSERM (Institut National de la Sante et de la Recherche Medicale), UNIVERSITE DE BRETAGNE OCCIDENTALE
    Inventors: Laurent Corcos, Catherine Le Jossic-Corcos
  • COMPOSITIONS AND METHODS FOR INHIBITING TUMOR DEVELOPMENT CAUSED BY CHEMOTHERAPY INDUCED SENESCENCE
    Publication number: 20140199292
    Abstract: The present invention relates to products and compositions containing (i) a chemotherapeutic agent and (ii) at least an active compound chosen from CCL2 inhibitors, CCR2 inhibitors, NF-?B inhibitors, PARP-1 inhibitors and ATM inhibitors, as a combined preparation for simultaneous, separate or sequential use for inhibiting tumor development caused by tumor cell senescence induced by said chemotherapeutic agent. The invention also refers to a method for monitoring the response to a chemotherapeutic agent of a patient suffering from a cancer, and to a method for predicting the tumor size evolution and/or the onset of metastasis in a patient suffering from a cancer.
    Type: Application
    Filed: March 14, 2012
    Publication date: July 17, 2014
    Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Corine Bertolotto-Ballotti, Robert Ballotti, Mickael Ohanna, Sandy Giuliano
  • COMPOSITIONS AND METHODS TO IMMUNIZE AGAINST HEPATITIS C VIRUS
    Publication number: 20140199763
    Abstract: Compositions comprising viral antigens and antigenic peptides corresponding to or derived from Hepatitis C virus (HCV) proteins or fragments thereof, fused to heavy and/or light chain of antibodies, or fragments thereof specific for dendritic cells (DCs) are described herein. Included herein are immunostimulatory compositions (HCV vaccines, HCV antigen presenting dendritic cells, etc.) and methods for increasing effectiveness of HCV antigen presentation by an antigen presenting cell, for a treatment, a prophylaxis or a combination thereof against hepatitis C in a human subject, and methods of providing immunostimulation by activation of one or more dendritic cells, methods to treat or prevent hepatitis C.
    Type: Application
    Filed: January 10, 2014
    Publication date: July 17, 2014
    Applicants: Institut National de la Sante et de la Recherche Medicale ( INSERM), Baylor Research Institute
    Inventors: Helene Dutartre, Yves Levy, Jacques Banchereau, Gerard Zurawski
  • Modified gram-negative bacteria for use as vaccines
    Patent number: 8778655
    Abstract: The invention relates to Gram-negative bacteria carrying an inactivated gene encoding a glycosyltransferase involved in the synthesis of the core of the LPS of said Gram-negative bacteria, wherein said inactivated gene results in the synthesis of a LPS having a modified core. These strains have an attenuated virulence but induce a humoral immunity sufficient for ensuring vaccination of the host.
    Type: Grant
    Filed: September 21, 2010
    Date of Patent: July 15, 2014
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique—CNRS, Universite de la Mediterranee—Aix-Marseille II, Universidad de Navarra
    Inventors: Jean-Pierre Gorvel, Vilma Arce Gorvel, Maite Iriarte, Ignacio Moriyon, Raquel Conde-Alvarez
  • Neuronal viability factor and use thereof
    Patent number: 8779093
    Abstract: This invention relates to methods and compositions for detection and treatment of neurodegenerative diseases. In particular, the invention relates to polypeptides that can protect against neuron degeneration, nucleic acid molecules that encode such polypeptides, and antibodies that recognize said polypeptides.
    Type: Grant
    Filed: September 10, 2009
    Date of Patent: July 15, 2014
    Assignee: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Thierry Leveillard, Celine Jaillard, Jose-Alain Sahel